Sotagliflozin改进了非糖尿病心脏病患者的心脏功能和生活质量,提供了有希望的新治疗。 Sotagliflozin improved heart function and quality of life in non-diabetic heart failure patients, offering a promising new treatment.

Sotagliflozin是最初为糖尿病研制的口服药物,根据美国心脏协会2025年科学会议提出的SOTA P CARDIA试验的新数据,对于心脏衰竭的非糖尿病病人来说,通过保留弹射分数(HFPEF)对患有心脏病的非糖尿病病人有重大好处。 Sotagliflozin, an oral medication originally developed for diabetes, showed significant benefits in non-diabetic patients with heart failure with preserved ejection fraction (HFpEF), according to new data from the SOTA P CARDIA trial presented at the American Heart Association’s 2025 Scientific Sessions. 对88名病人进行的随机、双盲研究发现,左心肌质量、非心功能、行走能力和生活质量都有改善,在行使能力方面有有意义的趋势。 The randomized, double-blind study of 88 patients found improvements in left ventricular mass, diastolic function, walking ability, and quality of life, with a meaningful trend in exercise capacity. HFpEF 影响了 670 万美国心力衰竭患者中的一半以上，住院风险很高，一年死亡率约为 25%。 HFpEF, affecting over half of the 6.7 million Americans with heart failure, carries a high risk of hospitalization and a one-year mortality rate of about 25%. 这些发现是首次显示非糖尿病HFpEF患者明显的优势,支持sotagliflozin作为一个有前途的治疗选择. The findings, the first to show clear advantages in non-diabetic HFpEF patients, support sotagliflozin as a promising treatment option.